Your browser is no longer supported. Please, upgrade your browser.
Settings
ZSAN Zosano Pharma Corporation daily Stock Chart
ZSAN [NASD]
Zosano Pharma Corporation
Index- P/E- EPS (ttm)-2.37 Insider Own0.23% Shs Outstand55.36M Perf Week5.42%
Market Cap31.11M Forward P/E- EPS next Y-0.14 Insider Trans0.00% Shs Float54.21M Perf Month-43.23%
Income-37.60M PEG- EPS next Q-0.31 Inst Own14.20% Short Float8.83% Perf Quarter-59.86%
Sales- P/S- EPS this Y38.70% Inst Trans14.18% Short Ratio1.53 Perf Half Y-63.97%
Book/sh0.50 P/B1.12 EPS next Y69.10% ROA-96.60% Target Price9.00 Perf Year-88.14%
Cash/sh0.11 P/C4.94 EPS next 5Y- ROE-310.50% 52W Range0.41 - 5.46 Perf YTD-63.03%
Dividend- P/FCF- EPS past 5Y47.10% ROI- 52W High-90.14% Beta2.60
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low32.96% ATR0.10
Employees56 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)41.06 Volatility11.23% 19.28%
OptionableNo Debt/Eq1.14 EPS Q/Q43.70% Profit Margin- Rel Volume0.24 Prev Close0.56
ShortableYes LT Debt/Eq0.65 EarningsMar 19 AMC Payout- Avg Volume3.12M Price0.54
Recom1.50 SMA20-4.29% SMA50-34.03% SMA200-70.67% Volume584,924 Change-4.18%
Apr-17-19Initiated Maxim Group Buy $8
Mar-24-17Initiated Piper Jaffray Overweight $4
Aug-11-16Downgrade Ladenburg Thalmann Buy → Neutral
Nov-11-15Reiterated ROTH Capital Buy $11 → $7
Sep-29-15Reiterated ROTH Capital Buy $20 → $11
Feb-23-15Initiated ROTH Capital Buy $20
Mar-13-20 08:00AM  Zosano Pharma Reports Fourth Quarter and Fiscal Year 2019 Financial Results GlobeNewswire
Mar-11-20 09:23AM  Biotech Maven Hal Mintz Snaps Up These 3 Small Biotech Stocks TipRanks
Mar-06-20 05:15PM  Zosano Pharma Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
Mar-05-20 08:00AM  Zosano Pharma Announces $11 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -11.89%
Mar-04-20 05:58PM  Nearly $300M, six CEOs and dead-ends later, East Bay drugmaker gets date with FDA for migraine treatment American City Business Journals
08:00AM  Zosano Pharma Announces FDA Acceptance of 505(b)(2) New Drug Application for Qtrypta for the Acute Treatment of Migraine GlobeNewswire
Feb-12-20 09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga -48.44%
08:20AM  Zosano Pharma Announces Pricing of $8.0 Million Public Offering of Common Stock and Warrants GlobeNewswire
Feb-11-20 04:35PM  Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire +17.93%
Jan-23-20 12:24PM  Did Zosano Pharma Corporation (NASDAQ:ZSAN) Insiders Buy Up More Shares? Simply Wall St.
Dec-23-19 05:42PM  Hemophilia gene therapy leads Bay Area trio of year-end FDA approval requests American City Business Journals
08:00AM  Zosano Announces FDA Submission of New Drug Application for Qtrypta GlobeNewswire
Dec-04-19 01:22PM  Edited Transcript of ZSAN earnings conference call or presentation 14-Nov-19 9:30pm GMT Thomson Reuters StreetEvents -8.11%
Nov-28-19 11:00PM  Is Zosano Pharma Corp (ZSAN) A Good Stock To Buy? Insider Monkey
Nov-27-19 09:29AM  Zosano Announces Pricing of Registered Direct Offering GlobeNewswire +22.37%
Nov-14-19 04:05PM  Zosano Pharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
08:07AM  The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing Benzinga
Nov-13-19 04:30PM  Zosano Pharma Announces Completion of Pre-NDA Meetings with FDA for Qtrypta GlobeNewswire
Nov-07-19 09:00AM  Zosano Pharma to Host Conference Call on Third Quarter 2019 Financial Results and Provide Operational Update GlobeNewswire
Oct-24-19 09:00AM  Zosano Pharma Initiates Phase 2/3 Clinical Study in Cluster Headache GlobeNewswire +6.19%
Oct-23-19 04:05PM  Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +7.62%
Oct-08-19 09:00AM  Zosano Pharma Announces CEO Transition GlobeNewswire
Sep-27-19 04:05PM  Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.29%
Sep-26-19 09:00AM  Zosano Pharma to Present at the Cantor Global Healthcare Conference GlobeNewswire
Sep-18-19 08:30AM  Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development GlobeNewswire
Sep-09-19 08:30AM  Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta Long-Term Safety Study at the Congress of the International Headache Society GlobeNewswire
Sep-03-19 06:02PM  Edited Transcript of ZSAN earnings conference call or presentation 14-Aug-19 8:30pm GMT Thomson Reuters StreetEvents -5.61%
09:00AM  Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference GlobeNewswire
Aug-23-19 09:00AM  Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society GlobeNewswire -6.19%
Aug-14-19 04:05PM  Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
09:00AM  Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache GlobeNewswire
Aug-08-19 08:38PM  Aisling Capital Management LP Buys Zosano Pharma Corp GuruFocus.com
Aug-07-19 04:05PM  Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update GlobeNewswire
Jul-24-19 12:19PM  Read This Before Selling Zosano Pharma Corporation (NASDAQ:ZSAN) Shares Simply Wall St.
Jul-15-19 08:19AM  Zosano Pharma Presents Positive Migraine-ACT Results Benzinga
06:00AM  Zosano Pharma Presents Migraine-ACT Scores for Qtrypta at the American Headache Society (AHS) Annual Scientific Meeting GlobeNewswire
Jul-08-19 07:30AM  In Search of That 'Tenbagger' TheStreet.com
Jul-03-19 08:30AM  Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference GlobeNewswire
Jul-01-19 04:05PM  Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting GlobeNewswire
Jun-18-19 06:00AM  Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta GlobeNewswire
May-14-19 04:05PM  Zosano Pharma Reports First Quarter 2019 Financial Results GlobeNewswire
02:30PM  Zosano Pharma Corp. to Host Earnings Call ACCESSWIRE
May-09-19 09:00AM  Zosano Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
May-08-19 04:30PM  Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update GlobeNewswire
Apr-22-19 02:57PM  Zosano Pharma Corporation (NASDAQ:ZSAN): Immense Growth Potential? Simply Wall St. +7.65%
Apr-16-19 08:30AM  Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain GlobeNewswire
Apr-09-19 09:00AM  Zosano Announces Pricing of Public Offering of Common Stock GlobeNewswire -26.75%
Apr-08-19 04:01PM  Zosano Pharma Announces Proposed Public Offering of Common Stock GlobeNewswire
Mar-14-19 04:05PM  Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results Business Wire
02:30PM  Zosano Pharma Corp. to Host Earnings Call ACCESSWIRE
Mar-11-19 04:30PM  Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference GlobeNewswire +10.08%
Mar-07-19 04:30PM  Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update GlobeNewswire
Feb-25-19 07:45AM  Detailed Research: Economic Perspectives on Zosano Pharma, Appian, Ross Stores, Alleghany, ZAGG, and Lindsay What Drives Growth in Today's Competitive Landscape GlobeNewswire +12.11%
Feb-22-19 10:40AM  Four Healthcare Stocks Looking to Close Out a Strong Week ACCESSWIRE -24.33%
07:30AM  FDA Events Can Send Stocks Soaring: Here's One That Absolutely No One Is Talking About ACCESSWIRE
Feb-21-19 01:45PM  Watch These Tech Stocks Push The Limit ACCESSWIRE +171.49%
12:07PM  What Kind Of Shareholder Owns Most Zosano Pharma Corporation (NASDAQ:ZSAN) Stock? Simply Wall St.
06:00AM  Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta for the Acute Treatment of Migraine Disease GlobeNewswire
Jan-31-19 08:30AM  Zosano Announces Publication of Positive Data on Qtryptas Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines GlobeNewswire
Jan-16-19 08:30AM  Zosano Appoints Linda Grais M.D., J.D. to Board of Directors GlobeNewswire
Dec-12-18 08:30AM  Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta for M207 GlobeNewswire
Nov-14-18 04:05PM  Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update GlobeNewswire
Nov-07-18 04:30PM  Zosano Pharma to Host Conference Call on Third Quarter 2018 Financial Results and Provide Operational Update GlobeNewswire +7.30%
Oct-25-18 09:15AM  Recent Analysis Shows Stellus Capital Investment, Nuance Communications, ProPetro Holding, Sanchez Energy, Granite Point Mortgage Trust, and Zosano Pharma Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-23-18 08:30AM  Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study GlobeNewswire
Oct-18-18 08:00AM  Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients Perspective GlobeNewswire
Oct-16-18 08:30AM  Zosano Appoints New Chief Financial Officer GlobeNewswire
Oct-03-18 08:30AM  Zosano Pharma Engages Contract Manufacturer as Part of the Commercialization Strategy for M207 GlobeNewswire
Sep-26-18 08:30AM  Zosano Pharma Enters Into Capital Equipment Lease Agreement With Trinity Capital Investment GlobeNewswire
Sep-19-18 08:30AM  Zosano Pharma Completes Manufacture of M207 Registration Batches GlobeNewswire
Sep-14-18 09:56AM  Shareholders Should Check If Insiders Own Shares In Zosano Pharma Corporation (NASDAQ:ZSAN) Simply Wall St.
Sep-06-18 08:30AM  Zosano Pharma to Present Phase 3 Safety Study Update for ADAM Technology in the Delivery of Zolmitriptan at the 5th Annual Transdermal & Intradermal Drug Delivery Systems Conference GlobeNewswire
Sep-05-18 08:30AM  Zosano Pharma and Collaborators to Present Efficacy Data for M207 in the Treatment of Migraine at the 17th Biennial Migraine Trust International Symposium (MTIS) GlobeNewswire -5.48%
Aug-09-18 04:00PM  Zosano Pharma Reports Second Quarter 2018 Financial Results and Operational Update GlobeNewswire -5.05%
02:30PM  Zosano Pharma Corp. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:30AM  Zosano Pharma to Host Conference Call on Second Quarter 2018 Financial Results and Provide Operational Update GlobeNewswire
Jul-30-18 07:20AM  Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks ACCESSWIRE
Jul-17-18 08:30AM  Zosano Announces Positive Data from a Nonclinical Evaluation of Pharmacokinetics and Skin Tolerability Study for ADAM Technology for the Delivery of Zolmitriptan GlobeNewswire +13.04%
Jul-02-18 07:25AM  Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities ACCESSWIRE
Jun-28-18 07:27AM  Zosano Pharma (ZSAN) Stock Can Reach $19 in the Next 12 Months, Says BTIG SmarterAnalyst
Jun-27-18 02:00PM  Zosano to Present Additional Analyses from the ZOTRIP Pivotal Study on Pain Relief and Recurrence at the 2018 American Headache Society (AHS) Meeting GlobeNewswire
Jun-20-18 08:30AM  Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics GlobeNewswire
May-31-18 08:20AM  Market Trends Toward New Normal in ANSYS, Pearson, Qualys, H. B. Fuller, Cabot Microelectronics, and Zosano Pharma Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-30-18 07:25AM  Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks ACCESSWIRE
May-23-18 08:30AM  Zosano Announces Publication of Most Bothersome Symptom Data from the ZOTRIP Pivotal Study in Headache: The Journal of Head and Face Pain GlobeNewswire
May-22-18 08:30AM  Zosano Appoints Steven A. Elms to Board of Directors GlobeNewswire
May-15-18 04:00PM  Zosano Pharma Reports First Quarter 2018 Financial Results and Operational Update GlobeNewswire
May-14-18 08:30AM  Zosano Reaches Another Enrollment Milestone in M207-ADAM Long-term Safety Study GlobeNewswire +10.54%
May-08-18 04:05PM  Zosano Pharma to Host Conference Call on First Quarter 2018 Financial Results and Provide Operational Update GlobeNewswire
Apr-05-18 08:15AM  Analysis: Positioning to Benefit within Euronet Worldwide, Innospec, Zosano Pharma, Ardelyx, Crown Castle International, and Aldeyra Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Apr-03-18 04:05PM  Zosano Announces Closing of Public Offering of Common Stock GlobeNewswire
Apr-02-18 12:56PM  Zosano Pharma to Host Conference Call to Provide Operational Update GlobeNewswire
Mar-29-18 09:00AM  Zosano Announces Pricing of Public Offering of Common Stock GlobeNewswire -45.04%
08:17AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:37AM  Zosano Pharma's stock plummets after stock offering filed, assumed to price at deep discount MarketWatch
Mar-20-18 07:30AM  Wired News Zosano Reports Enrollment Milestone in its M207-ADAM Study ACCESSWIRE
Mar-16-18 11:02AM  Should You Buy Zosano Pharma Corporation (NASDAQ:ZSAN) Now? Simply Wall St.
08:30AM  Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study GlobeNewswire
Mar-12-18 08:45AM  Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update GlobeNewswire
Mar-09-18 09:07AM  The Market In 5 Minutes: Trump And Kim Jung Un, Toys 'R' Us Liquidation, Zosano's Move, Big Payrolls Beat Benzinga
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WALKER JOHN PETERPresident & CEOApr 11Buy3.50100,000350,000280,228Apr 18 04:25 PM